This HTML5 document contains 65 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n8http://linked.opendata.cz/resource/drugbank/drug/DB00867/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00867/identifier/chemspider/
n24http://bio2rdf.org/drugbank:
n19http://www.drugs.com/cons/
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00867/identifier/wikipedia/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00867/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/mesh/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00867/identifier/kegg-compound/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00867/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00867/identifier/pubchem-substance/
n22http://linked.opendata.cz/ontology/sukl/drug/
n23http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00867/identifier/kegg-drug/

Statements

Subject Item
n2:DB00867
rdf:type
n3:Drug
n3:description
Adrenergic beta-agonist used to control premature labor. [PubChem]
n3:group
approved
n3:halfLife
1.7-2.6 hours
n3:indication
For the treatment and prophylaxis of premature labour
n3:manufacturer
n5:271B5272-363D-11E5-9242-09173F13E4C5 n5:271B5273-363D-11E5-9242-09173F13E4C5 n5:271B5271-363D-11E5-9242-09173F13E4C5
owl:sameAs
n21:DB00867 n24:DB00867
dcterms:title
Ritodrine
adms:identifier
n7:30971 n8:DB00867 n12:33572 n13:46505273 n14:D02359 n15:PA451258 n16:Ritodrine n17:C07239
n3:mechanismOfAction
Ritodrine is beta-2 adrenergic agonist. It binds to beta-2 adrenergic receptors on outer membrane of myometrial cell, activates adenyl cyclase to increase the level of cAMP which decreases intracellular calcium and leads to a decrease of uterine contractions.
n3:packager
n5:271B5270-363D-11E5-9242-09173F13E4C5
n3:synonym
Ritodrina DU-21220 Ritodrinium Yutopar Ritodrine
n3:toxicity
LD<sub>50</sub>=64mg/kg (mice, IV); LD<sub>50</sub>=540 mg/kg (mice, oral); LD<sub>50</sub>=85 mg/kg (rat, IV)
n3:proteinBinding
~56%
n3:salt
n3:synthesisReference
Naoki Yamazaki, Yoshimasa Fukuda, Yoshiaki Shibazaki, Tetsutarou Niizato, Isao Kosugi, Shin Yoshioka, "(-)-ritodrine, therapeutic compositions and use, and method of preparation." U.S. Patent US5449694, issued July, 1992.
n9:hasConcept
n10:M0019137
foaf:page
n19:ritodrine-oral-intravenous.html
n3:IUPAC-Name
n4:271B5278-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B527E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B527D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B527A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B527B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B527C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5276-363D-11E5-9242-09173F13E4C5 n4:271B528E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5277-363D-11E5-9242-09173F13E4C5 n4:271B5290-363D-11E5-9242-09173F13E4C5 n4:271B5274-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5275-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n23:G02CA01
n3:H-Bond-Acceptor-Count
n4:271B5284-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5285-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B527F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5280-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5282-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5281-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5283-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
26652-09-5
n3:category
n3:Bioavailability
n4:271B528A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B528C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B528D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B528F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5289-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5288-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B528B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5279-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5286-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5287-363D-11E5-9242-09173F13E4C5